GlycoMimetics (GLYC)
(Delayed Data from NSDQ)
$0.26 USD
0.00 (-1.11%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $0.26 0.00 (1.01%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
GlycoMimetics, Inc. [GLYC]
Reports for Purchase
Showing records 41 - 60 ( 158 total )
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Reminder to Join Our Call Wednesday On Upro''s Development in China for AML
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Upcoming Call With Apollomics on Upro''s Development in China for AML
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
2Q21 Results; Uproleselan Development Steams Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
2Q21 Update: Investment Thesis Stronger With New CEO & 2022 Data Readouts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
3rd Investigator-Sponsored Study for Upro Started; Expect Data-Rich 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Upro + VenAza Combo Now Being Tested in Unfit AML Patients; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
First Patient Dosed with Uproleselan in Phase 2 in Multiple Myeloma
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
1Q21 Update - Management Continues to Execute with More Progress Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
1Q21 Results; Ph3 Uproleselan Trial in r/r AML Expected to Reach Full Enrollment by YE21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
AACR 2021 Presentations for GMI-1359 and GMI-1757 Look Promising
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
AACR Preclinical and Clinical Data Highlights Pipeline Advances
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z